News and Events >CU Options Cancer Theraputic to Serendipity Pharmaceuticals, Inc.

CU Options Cancer Theraputic to Serendipity Pharmaceuticals, Inc.

April 12, 2005

Boulder, CO - The University of Colorado (CU) today announced that it has exclusively optioned to Serendipity Pharmaceuticals, Inc, also of Boulder, the patented cancer therapeutic Doxoform.

Doxoform is a prodrug to the active metabolite of the chemotherapeutic agent doxorubicin that readily cross-links DNA. As such, it is a highly potent and improved form of doxorubicin, active against both sensitive and resistant tumor cells. Since doxorubicin is a chemotherapeutic agent whose common systemic use is still limited by toxic side effects, a new highly potent form with reduced side effects would be highly valuable for the systemic treatment of various cancers. Dr. Tad Koch, Professor of Chemistry at the University of Colorado at Boulder developed Doxoform. Dr. Koch was quoted as saying, "My current and former graduate students, postdoctoral associates, and I are all very excited about the possibility that our research discoveries will be explored further by Serendipity Pharmaceuticals with the goal of improved treatments for cancer."

Serendipity Pharmaceuticals expects to develop therapy options for the treatment of solid tumors based on Doxoform, a patented chemotherapeutic drug related to the well known and widely used chemotherapeutic compound doxorubicin. Doxoform is a highly potent, patented compound whose metabolites are related to one of the most prescribed chemotherapeutic drugs, doxorubicin.